Restricted specificity of peripheral alloreactive memory B cells in HLA-sensitized patients awaiting a kidney transplant

Kidney International

Volumn 87, Issue 6, 2015, Pages 1230-1240

  Snanoudj, Renaud ^a,b   Claas, Frans H J ^c   Heidt, Sebastiaan ^c   Legendre, Christophe ^a,b   Chatenoud, Lucienne ^a,b   Candon, Sophie ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

continuous renal replacement therapy; lymphocytes

Indexed keywords

HLA ANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G;

ADULT; ANTIBODY DETECTION; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; END STAGE RENAL DISEASE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SENSITIZATION; B LYMPHOCYTE; BLOOD; CELL CULTURE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; TIME FACTOR;

ADULT; B-LYMPHOCYTES; CELLS, CULTURED; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HLA ANTIGENS; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TIME FACTORS;

EID: 84930273749     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.390     Document Type: Article

References (47)

1. Einecke G, Sis B, Reeve J et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
2. Gaston RS, Cecka JM, Kasiske BL et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68-74.
3. Lefaucheur C, Loupy A, Hill GS et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406.
4. Mohan S, Palanisamy A, Tsapepas D et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 2012; 23: 2061-2071.
5. Marfo K, Lu A, Ling M et al. Desensitization protocols and their outcome. Clin J Am Soc Nephrol 2011; 6: 922-936.
6. Montgomery RA, Lonze BE, King KE et al. Desensitization in HLAincompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-326.
7. McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Annu Rev Immunol 2005; 23: 487-513.
8. Elgueta R, de Vries VC, Noelle RJ. The immortality of humoral immunity. Immunol Rev 2010; 236: 139-150.
9. Good-Jacobson KL, Tarlinton DM. Multiple routes to B-cell memory. Int Immunol 2012; 24: 403-408.
10. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357: 1903-1915.
11. Leyendeckers H, Odendahl M, Lohndorf A et al. Correlation analysis between frequencies of circulating antigen-specific IgG-bearing memory B cells and serum titers of antigen-specific IgG. Eur J Immunol 1999; 29: 1406-1417.
12. Cambridge G, Leandro MJ, Edwards JC et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48: 2146-2154.
13. Vallerskog T, Gunnarsson I, Widhe M et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007; 122: 62-74.
14. Smith RM, Jones RB, Guerry MJ et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64: 3760-3769.
15. van der Kolk LE, Baars JW, Prins MH et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002; 100: 2257-2259.
16. Mulder A, Eijsink C, Kardol MJ et al. Identification, isolation, and culture of HLA-A2-specific B lymphocytes using MHC class I tetramers. J Immunol 2003; 171: 6599-6603.
17. Han M, Rogers JA, Lavingia B et al. Peripheral blood B cells producing donor-specific HLA antibodies in vitro. Hum Immunol 2009; 70: 29-34.
18. Zachary AA, Kopchaliiska D, Montgomery RA et al. HLA-specific B cells: I. A method for their detection, quantification, and isolation using HLA tetramers. Transplantation 2007; 83: 982-988.
19. Heidt S, Roelen DL, de Vaal YJ et al. A NOVel ELISPOT assay to quantify HLA-specific B cells in HLA-immunized individuals. Am J Transplant 2012; 12: 1469-1478.
20. Perry DK, Pollinger HS, Burns JM et al. Two novel assays of alloantibodysecreting cells demonstrating resistance to desensitization with IVIG and rATG. Am J Transplant 2008; 8: 133-143.
21. Lynch RJ, Silva IA, Chen BJ et al. Cryptic B cell response to renal transplantation. Am J Transplant 2013; 13: 1713-1723.
22. Crotty S, Aubert RD, Glidewell J et al. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 2004; 286: 111-122.
23. Duquesnoy RJ. Antibody-reactive epitope determination with HLAMatchmaker and its clinical applications. Tissue Antigens 2011; 77: 525-534.
24. Duquesnoy RJ. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol 2006; 67: 847-862.
25. Mamani-Matsuda M, Cosma A, Weller S et al. The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood 2008; 111: 4653-4659.
26. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298: 2199-2202.
27. Duquesnoy RJ, Askar M. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLADQ, and HLA-DP. Hum Immunol 2007; 68: 12-25.
28. Duquesnoy RJ, Marrari M. Correlations between Terasaki?s HLA class I epitopes and HLAMatchmaker-defined eplets on HLA-A, -B and -C antigens. Tissue Antigens 2009; 74: 117-133.
29. Marrari M, Duquesnoy RJ. Correlations between Terasaki?s HLA class II epitopes and HLAMatchmaker-defined eplets on HLA-DR and -DQ antigens. Tissue Antigens 2009; 74: 134-146.
30. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA et al. "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008; 86: 1111-1115.
31. Ravindranath MH, Kaneku H, El-Awar N et al. Antibodies to HLA-E in nonalloimmunized males: pattern of HLA-Ia reactivity of anti-HLA-Epositive sera. J Immunol 2010; 185: 1935-1948.
32. Sicard A, Amrouche L, Suberbielle C et al. Outcome of kidney transplantations performed with preformed donor-specific antibodies of unknown etiology. Am J Transplant 2014; 14: 193-201.
33. Scornik JC, Meier-Kriesche HU. Blood transfusions in organ transplant patients: mechanisms of sensitization and implications for prevention. Am J Transplant 2011; 11: 1785-1791.
34. Bianchi DW, Zickwolf GK, Weil GJ et al. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc Natl Acad Sci USA 1996; 93: 705-708.
35. McHeyzer-Williams M, Okitsu S, Wang N et al. Molecular programming of B cell memory. Nat Rev Immunol 2011; 12: 24-34.
36. Dogan I, Bertocci B, Vilmont V et al. Multiple layers of B cell memory with different effector functions. Nat Immunol 2009; 10: 1292-1299.
37. Kasturi SP, Skountzou I, Albrecht RA et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011; 470: 543-547.
38. SivaSai KS, Jendrisak M, Duffy BF et al. Chimerism in peripheral blood of sensitized patients waiting for renal transplantation: clinical implications. Transplantation 2000; 69: 538-544.
39. Sahota A, Gao S, Hayes J et al. Microchimerism and rejection: a metaanalysis. Clin Transplant 2000; 14: 345-350.
40. Baumjohann D, Preite S, Reboldi A et al. Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype. Immunity 2013; 38: 596-605.
41. Zachary AA, Lucas DP, Montgomery RA et al. Rituximab prevents an anamnestic response in patients with cryptic sensitization to HLA. Transplantation 2013; 95: 701-704.
42. Duquesnoy RJ. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. I. Description of the algorithm. Hum Immunol 2002; 63: 339-352.
43. Lobashevsky AL, Senkbeil RW, Shoaf JL et al. The number of amino acid residues mismatches correlates with flow cytometry crossmatching results in high PRA renal patients. Hum Immunol 2002; 63: 364-374.
44. Dankers MK, Witvliet MD, Roelen DL et al. The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched human leukocyte antigens. Transplantation 2004; 77: 1236-1239.
45. Goodman RS, Taylor CJ, O?Rourke CM et al. Utility of HLAMatchmaker and single-antigen HLA-antibody detection beads for identification of acceptable mismatches in highly sensitized patients awaiting kidney transplantation. Transplantation 2006; 81: 1331-1336.
46. Claas FH, Witvliet MD, Duquesnoy RJ et al. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation 2004; 78: 190-193.
47. Bohnhorst JO, Bjorgan MB, Thoen JE et al. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren?s syndrome. J Immunol 2001; 167: 3610-3618.